Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma

Jesmin Akter, Yutaka Katai, Parvin Sultana, Hisanori Takenobu, Masayuki Haruta, Ryuichi P. Sugino, Kyosuke Mukae, Shunpei Satoh, Tomoko Wada, Miki Ohira, Kiyohiro Ando and Takehiko Kamijo

© The Author(s) 2021

INTRODUCTION

Neuroblastoma (NB) is a pediatric tumor of the sympathetic nervous system that accounts for 8–10% of all childhood cancers and 15% of pediatric oncology deaths. Genomic studies revealed that patients with high-risk NB frequently harbored recurrent MYCN amplification (37%), TERT rearrangements (23%), and alpha thalassemia mental retardation X-linked (ATRX) mutations or deletions (11%) [1, 2]. Mutations in ATRX were found to be mutually exclusive with TERT promoter mutations and MYCN amplification, and defined a distinct subgroup of older NB patients with poor outcomes [1–3]. In addition to human NB, loss-of-function (LoF) mutations in ATRX have frequently been detected in multiple malignancies [4–7], and have been implicated in the telomerase-independent telomere maintenance alternative lengthening of telomeres (ALT) mechanism, which has been reported in 24% of high-risk NB [8–10]. The ATRX/DAXX complex was found to be less abundant in ALT-positive NB tumors due to ATRX mutations (55%) or low protein expression [9], which supports the relationship between the ATRX status and ALT. Previous studies described a link between the loss of ATRX, replication stress (RS), DNA damage, copy number alterations, and genomic instability [11–15]. ATRX has more recently been suggested to bind to the G-quadruplex (G4) structure [16], with its loss leading to an increase in the G4 structure or the formation of stable DNA:RNA hybrids (R-loops), which is considered to induce replication fork stalling and collapse and the generation of DNA double-strand breaks (DSBs) at telomeres, suggesting a role for ATRX in the resolution of the G4 structure and regulation of R-loops [11, 17]. ATRX also forms a complex with DAXX to deposit H3.3, which prevents the formation of the G4 structure [11, 18, 19] or R-loops [17], thereby maintaining fork stability during acute RS.

A recent study demonstrated that somatic mutations in TP53 pathway genes were significantly enriched in ALT-positive tumors [9]. Furthermore, p53 pathway aberrations were frequently detected in ALT NB cell lines [20]. In ALT-positive tumors, ATRX mutations are commonly connected to mutations in the tumor suppressor gene TP53 [4, 21, 22], and the LoF of p53 activates the ALT pathway [20]. Collectively, these findings highlight the involvement of both ATRX mutations and p53 pathway aberrations in NB tumorigenesis in terms of ALT. In mouse neural progenitor cells (mNPCs), ATRX deficiency promoted p53-dependent apoptosis through the accumulation of DNA damage in the embryonic brain caused by DNA RS [15]. However, DNA damage accumulation and cell death were effectively rescued in ATRX/p53 double mutant mice [23]. Although the loss of p53 promotes the growth of emergent cancer cells by reducing RS-induced DNA damage [24], the mechanisms by which p53 deficiency suppresses RS in terms of ATRX loss remain unknown.

To avoid RS, G4 helicases prevent G4-induced genome instability by resolving G4 structures [25, 26]. Another Fanconi
anemia (FA) pathway protein, FANCD2, plays a key role in limiting RS by controlling the stability of stalled replication forks in cells or tumors lacking BRAC1/2 [27, 28], and has been shown to cooperate with ATRX to limit RS and promote the homologous recombination (HR)-dependent repair of DSBs [29]. In addition to the H3.3 chaperone activity of ATRX/DAXX, the histone H3 deposition activity of FANCD2 was necessary for protecting stalled replication forks [29]. Previous studies also revealed the transcriptional regulation of G4 DNA helicases or FA pathway genes by p53, which are involved in telomere maintenance, DNA repair, and the centromere structure [30–32]. However, the impact of this regulation in ATRX-deficient cells remains unclear.

In the present study, we revealed that ATRX depletion in TP53 wild-type (wt) NB cells was associated with an increased frequency of DSBs and a subsequent RS-induced DNA damage response (DDR), which was impaired by the loss of p53 through the activation of G4 DNA helicases or the FA DNA repair pathway protein, FANCD2. Collectively, the present results indicate that p53 deficiency limits ATRX loss-induced RS/genome integrity in NB cells by regulating DNA repair mechanisms and replication fork stability.

MATERIALS AND METHODS

Cell lines

Human NB cell lines (NGP, NB-69 and SK-N-AS) were obtained from official cell banks (RIKEN Cell Bank, Tsukuba, Japan and ATCC, Manassas, VA, USA). Additional details of cell lines are in the Supplementary Materials and Methods.

ATRX CRISPR genome editing

CRISPR/Cas9 technology was used to generate ATRX KO cells. We designed three guide RNAs (gRNAs) against exons 4 and 5 of ATRX (Supplementary Fig. 1A, B). Further details are presented in the Supplementary Materials and Methods.

Supplementary information

Other materials and methods and Supplementary Tables S1 to S4 are described in Supplementary Information.

RESULTS

Generation of ATRX KO cells by CRISPR/Cas9 genome editing

We performed genome editing with the CRISPR/Cas9 system to recapitulate the cellular and molecular perspectives of ATRX deficiency in human NB using the NGP, NB-69, and SK-N-AS cell lines, which are wt for the gene. NGP and NB-69 cells have wt TP53 with MYCN amplifications and MYCN single copy, respectively; the MYCN single copy SK-N-AS cell line carries a TP53 truncation at its C terminus [33]. All three cell lines were selected for ATRX gene editing because neither displayed the ALT phenotype [8]; therefore, they were good comparable models for examining ATRX functions. Because ATRX is often co-mutated with TP53 in different tumors [8, 12, 20], our KO cells in three cell lines were characterized in detail (Supplementary Fig. 1, “Materials and methods”). As a control, we used bulked cells (referred to as Ctrl) and two clonal cell lines (referred to as Ctrl-1 and Ctrl-2) overexpressing Cas9 alone for NGP and NB-69 or SK-N-AS cells, respectively. We isolated four independent cell clones for NGP and three clones for both NB-69 and SK-N-AS with sequence-confirmed frameshift mutations in ATRX (Supplementary Fig. 1C) and completely devoid of ATRX protein expression, except for KO (C-3) NGP cells (Fig. 1A, Supplementary Figs. 2A, B, 3A and 4A). ATRX protein expression in ATRX KO cells for NGP and SK-N-AS were also verified using immunofluorescence (IF) (Supplementary Fig. 2A, B). Therefore, we successfully established several ATRX KO isogenic cells in TP53 wt NGP, NB-69, and TP53 truncated SK-N-AS cell lines for further study.

ATRX loss induces G4 formation and RS in TP53 wt NB cells

To clarify the biological consequences of ATRX deficiency, we initially examined the viability and clonogenic survival of ATRX KO NGP and NB-69 cells. An assessment of cell viability using the WST-8 assay showed that ATRX loss resulted in failed cell proliferation (Fig. 1A, Supplementary Fig. 3A), which is consistent with previous findings on ATRX deficiency in mNPCs and glioblastoma cells [12, 13]. We also observed lower clonogenic survival in ATRX KO than in Ctrl cells (Fig. 1B, Supplementary Fig. 3B).

ATRX plays a key role in the regulation of DNA replication and DNA damage repair pathways [13, 14, 34]. To ascertain whether ATRX depletion results in the accumulation of DNA damage at telomeres, we investigated γH2AX levels as a marker of stalled replication forks and DSBs. γH2AX levels were elevated in ATRX KO cells (Fig. 1C, Supplementary Fig. 3C), suggesting increases in stalled and collapsed replication forks. We also found enhanced telomeric DDR in ATRX KO NB cells, as indicated by the increased formation of γH2AX-associated telomere dysfunction-induced foci, TIF (Fig. 1D, E). This result suggests that ATRX also functions to protect against telomere DNA damage for telomere maintenance.

We then investigated whether increased levels of DNA damage under ATRX-deficient conditions were induced by the formation of G4. Consistent with previous findings [11, 35], G4 formation at stalled replication forks was associated with RS and DDR. Using a monoclonal antibody that recognizes the G4 structure in situ [8], the nuclear accumulation of G4 was found to be higher in ATRX KO cells than in Ctrl cells (Fig.1F, G and Supplementary Fig. 1H6), the nuclear accumulation of G4 was found to be higher in ATRX KO cells than in Ctrl cells (Fig.1F, G and Supplementary Fig. 1H6), the nuclear accumulation of G4 was found to be higher in ATRX KO cells than in Ctrl cells (Fig.1F, G and Supplementary Fig. 1H6).

Increased DNA damage induces the ATM/CHK2/p53 pathway

To elucidate ATRX-dependent transcriptional alterations and their functional consequences, we performed a microarray analysis of Ctrl and ATRX KO NB cells. According to GSEA, upregulated genes were implicated in DSBs and HR repair, cell cycle checkpoint activation, negative cell cycle regulation, and p53 pathway activation (Fig. 2A–E). This result suggested that the pathways involved in negative cell cycle regulation and DNA damage-induced p53 pathway activation were enhanced by ATRX deficiency in TP53 wt NB cells accompanied by transcriptional changes in their related gene members.

Oncogenesis (2021) 10:73
Fig. 1  ATRX loss induces G4 formation and RS in TP53 wt NGP cells. A Western blots show the depletion of ATRX protein expression in cell lysates prepared from Cas9 control (Ctrl) and ATRX KO (C-1, C-3, C-4, and C-21) NGP cells. β-Tubulin was used as a loading control. Lower panel, growth curves show that viability was lower in ATRX KO NGP cells than in Ctrl cells. Data are expressed as means ± standard deviation (SD), N = 3. A two-way ANOVA followed by a multiple comparison Bonferroni post hoc test was used to compare differences between groups (*p < 0.05 and **p < 0.01). B Clonogenic assay of Ctrl and ATRX KO NGP cells demonstrating the weaker proliferative abilities of KO cells than Ctrl cells. Lower panel, representative images for clonogenic formation are shown. Error bars represent SD from three technical replicates. **p < 0.01; A one-way ANOVA with Dunnett’s and Tukey’s test were used for statistical analyses. C Immunoblot showing activation of the DDR upon the depletion of ATRX, including the phosphorylation of histone H2AX on Ser-139 (γH2AX). D, E γH2AX/TelG immuno-FISH (D) shows increased TIF (telomere dysfunction-induced foci) in ATRX KO NGP cells. Arrows denote the colocalization of telomeric foci (red) and γH2AX signals (green). Cells were also stained with DAPI to visualize nuclei (blue). E Quantification of TIF+ cells among 100 cells analyzed in (D). F, G Coimmunofluorescence staining of ATRX-intact (Ctrl) and ATRX KO NGP cells with the anti-G-quadruplex (G4) antibody, 1H6 and anti-γH2AX. G Quantiﬁcation of G4+ cells among 100 cells analyzed in (F). H G4 (1H6)/TelG immuno-FISH reveals colocalization of G4 on telomeric region in ATRX KO NGP cells. Nuclei are counterstained with DAPI (blue). I Representative immunoblot analysis of p-KAP1 (Ser-824), KAP1, p-Chk1 (Ser-345), Chk1, p-RPA32 (Ser-33), and RPA32, showing the activation of RS arising from ATRX deficieny. β-Tubulin served as a loading control.
Proliferation inhibition by ATRX deficiency may be mediated by increases in DNA damage and activation of the ATM/CHK2/p53 pathway, supporting GSEA results. In response to DNA damage, p53 is phosphorylated by the ATM/CHK2 pathways, leading to cell cycle arrest or apoptosis [36]. Therefore, we investigated the involvement of ATM signaling in response to increased DNA damage. A western blot analysis of Ctrl and ATRX KO NGP cells demonstrated an increase in the activation of ATM in ATRX KO cells (Fig. 2F). ATR activation was not observed in Ctrl or ATRX KO cells (data not shown). Moreover, consistent with the formation of γH2AX in ATRX KO cells, the activation of ATM-dependent DSB signaling events was also detected in these cells, as revealed by increases in the phosphorylation of CHK2 and p53. Activated p53 then upregulated the expression of p21, which mediated the inhibition of proliferation. Moreover, p53 activation was observed in ATRX KO NB-69 cells, but downstream γH2AX and p21 only modest (Supplementary Fig. 3C). Collectively, these results revealed that the loss of ATRX in both MYCN-amplified and MYCN single copy TP53 wt NB cells promoted the accumulation of DNA damage and activated the cell cycle checkpoint pathway of DDR, the ATM-CHK2-p53 pathway, leading to cell cycle arrest.

**p53 inactivation limits ATRX loss-induced G4 formation and RS in TP53 wt NB cells**

The inactivation of p53 by a viral oncoprotein or TP53 mutation is commonly observed in ALT-positive cell lines [37]; ALT phenotype
in NB is associated with ATRX mutation and p53 pathway alterations [20]. To establish whether p53 deficiency with the loss of ATRX promotes ALT in NB cells, a C-terminally V5-tagged dominant-negative p53 (p53_R273H or p53_R175H) vector or control was stably transduced into ATRX KO NGP cells (Fig. 3A, left panel). Mutant p53 exerts a dominant-negative effect by preventing wt p53 from binding to the promoter of its target genes [38]. We initially investigated whether the forced expression of mutant p53 affected the survival of ATRX KO NGP cells. The results obtained showed that it significantly enhanced cell survival during cell cultures, indicating that mutant p53 reduced the ability of wt p53 to induce cell cycle arrest in ATRX KO NGP cells (Supplementary Fig. 6). The hallmarks associated with ALT were then examined in those cells. Similar to original ATRX KO NGP cells, p53_R273H or p53_R175H did not display C-circles (Supplementary Fig. 7B) or APBs (Supplementary Fig. 7C, D). Moreover, the total telomeric DNA content did not significantly differ between Ctrl and ATRX KO cells with the p53 mutant (Supplementary Fig. 7A). Therefore, NGP cells with ATRX deficiency and the p53 status cannot induce the ALT phenotype, which is associated with ATRX mutation and p53 pathway aberration in NB.

An investigation of DDR in p53-inactivated ATRX KO NGP cells revealed that the activation of the ATM/CHK2/p53 pathway decreased after p53 inactivation. The levels of key phosphoproteins involved in DDR were lower in ATRX KO NGP cells with the p53 mutant than in original KO cells (Fig. 3A, right panel). If of yH2AX also showed a weaker signal in p53-inactivated ATRX KO NGP cells (Fig. 3B, C), suggesting the influence of the p53 status on DDR-related cell cycle arrest upon the loss of ATRX. p53 inactivation abolished DDR and also prevented the formation of G4 (Fig. 3D, E) and suppressed the RS pathway in ATRX KO NGP cells (Fig. 3F). Furthermore, IF showed that p53 inactivation reduced phospho-RPA32 foci (Supplementary Fig. 8), consistent with immunoblot results. Therefore, p53 deficiency decreased ATRX loss-induced RS and DDR.

**ATRX deficiency-related DDR and RS are not induced in TP53 truncated (C terminus) SK-N-AS cells**

We attempted to confirm the ALT phenotype or p53 deficiency-related suppression of RS and DDR upon the loss of ATRX in the NB cell line with mutant TP53 and a MYCN single copy. A previous study reported an ALT phenotype associated with ATRX mutations, the lack of MYCN amplification, and p53 pathway alterations in NB [20]. Therefore, we selected the SK-N-AS cell line carrying a MYCN single copy and TP53 truncation at the C terminus [33]. We isolated several isogenic ATRX KO clones from SK-N-AS cells (discussed in the “Materials and methods” and “Results” sections). We then assessed the ALT status and found that the total telomere content and C-circle levels were below the ALT cut-off value (Supplementary Fig. 9A, B). However, APBs were partially detected in ATRX KO SK-N-AS cells (Supplementary Fig. 9C, D). Although APBs are one of the important markers of the ALT phenotype, C-circles are very specific and quantifiable markers of ALT [39]. Therefore, true ALT features were not observed in SK-N-AS cells after ATRX KO. These results suggest that, at least under the present experimental conditions, the ALT phenotype in NB cell lines was not associated with ATRX mutations, the lack of MYCN amplification, or p53 pathway aberrations.

WST-8 and colony formation assay results showed that the loss of ATRX did not significantly alter the viability of SK-N-AS cells (Fig. 4A, B). Moreover, yH2AX foci were not detected in ATRX KO SK-N-AS cells, indicating low levels of DNA damage (Fig. 4C) which is contrast with other findings following ATRX KO in TP53 wt SK-N-AS cells with prior p53 inactivation [34]. These relative phenotypic differences may be due to different experimental strategy or cell line specificity. As expected, ATRX deficiency did not induce the ATM/CHK2/p53 pathway (Fig. 4D). In addition, G4 formation was not detected in KO cells, leading to a suppressed RS response (Fig. 4E, F). In contrast to previous findings [15], these results indicated that p53 aberrations inhibited ATRX loss-induced RS related to DDR in NB cells.

**p53 inactivation leads to the upregulation of G4-resolving helicases and FA pathway proteins involved in replication fork protection**

When replication forks encounter DNA damage, G4 or R-loops may hinder fork progression and increase RS [40]. Under these conditions, specific proteins are recruited to the site of the stalled fork in order to manage the cellular response to this stress. Recent studies described an emerging class of DNA unwinding enzymes, known as helicases, which directly resolve the G4 DNA structure and remove RS during DNA replication [25, 26]. Another well-studied G4 helicase regulator or FA pathway protein, FANC D2, stabilizes and helps to restart stalled replication forks, thereby avoiding the generation of DNA damage and genome instability [27, 28]. To directly investigate how the p53 status affects ATRX loss-mediated RS-induced DSb, we searched for p53-regulated molecules involved in G4 structure resolution and replication fork protection, leading to the release of RS (Fig. 5A) [30–32]. We speculated that in the absence of ATRX, other G4-resolving helicases or DNA repair molecules may prevent RS during DNA replication. Accordingly, our initial aim was to clarify whether the inactivation of p53 triggered the upregulation of these molecules in Ctrl or ATRX KO NGP cells. Therefore, we compared the miRNA levels of six candidate genes implicated in G4 structure resolution and replication fork recovery in TP53 wt and p53-inactivated Ctrl or ATRX KO NGP cells. Five out of the six genes were upregulated after the inactivation of p53 (RTEL1, FANC D2, BLM, WRN, and RECQ4L) (Fig. 5B), which is consistent with previous findings on p53-dependent regulation [30–32]. Importantly, the induction of FANC D2 expression by p53 inactivation was the strongest. In addition to FANC D2, BLM expression also increased (Fig. 5B). These results appear to support previous findings showing that FANC D2 cooperated with BLM to facilitate stalled fork restart and suppress new origin firing; FANC D2 and BLM were also shown to have cooperative as well as independent roles in the context of stalled fork recovery [41]. Moreover, FANC D2 protein levels were higher in p53-inactivated Ctrl or ATRX KO cells than in TP53 wt Ctrl or ATRX KO NGP cells, which was consistent with qPCR data (Fig. 5B, C). These results support the previous finding of FANC D2 expression being markedly affected by the activation of p53 [30].

We also examined the expression of G4 helicases and FANC D2 at the mRNA level in Ctrl and ATRX KO SK-N-AS cells (Fig. 5D). An immunoblot analysis showed that FANC D2 protein levels remained unchanged between Ctrl or ATRX KO cells (Fig. 5E), suggesting that basal FANC D2 levels in SK-N-AS cells were sufficient for replication fork protection after the loss of ATRX.

Furthermore, ALT-positive NB cell lines with the TP53 mutation (SK-N-Fi) had higher FANC D2 and BLM expression levels than TP53 wt (NGP) and TP53-truncated (SK-N-AS) cells (Supplementary Fig. 10A). To date, no functional assays have been performed to establish whether these phenomena are the result of TP53 mutation in ALT-positive NB cells with ATRX LoF. In public datasets (R2, http://r2.amc.nl), FANC D2 expression levels were shown to be strongly associated with an advanced tumor stage and poor prognostic in human NB (Supplementary Fig. 10B, C). These findings suggest that upregulated FANC D2 expression may promote the ALT phenotype in ATRX-mutated NB. Collectively, these results indicate that FANC D2 expression levels significantly increased under the setting of p53 deficiency and may cooperate in the protection of stalled replication forks after the loss of ATRX.

**p53 deficiency limits ATRX loss-induced RS and genome instability through the FA pathway protein, FANC D2**

The loss of ATRX hinders fork stability by G4 or R-loop formation and increases RS [40]. Since ATRX
**Fig. 3**  *p53* inactivation limits ATRX loss-induced G4 formation and RS in TP53 wt NGP cells. **A** Left panel, for *p53* inactivation, C-terminally V5-tagged dominant-negative *p53* mutants (*p53*R273H or *p53*R175H) or a control empty vector (ShCtrl) were stably introduced by lentiviral infection into Ctrl or ATRX KO NGP cells. Western blotting using anti-V5 and anti-*p53* antibodies analyzed the expression levels of V5-tagged *p53* mutants. β-Actin was used as a loading control. Right panel, immunoblots for the expression of DSB checkpoint proteins in cell lysates prepared from the indicated samples. *p53* inactivation in ATRX KO NGP cells results in the loss of the DDR and *p53*-ATM checkpoint proteins. β-Tubulin was used as a loading control. As a positive control (P+), parental NGP cells were treated with doxorubicin (0.5 μg/mL) for 24 h. **B, C** γH2AX IF indicates decreased DDR after *p53* inactivation in ATRX KO NGP cells. NGP cells treated with doxorubicin (0.5 μg/mL, 24 h) were used as the positive control. **C** Quantification of γH2AX+ cells among 100 cells analyzed in (**B**). **D, E** IF staining of G4 (1H6) in the indicated cells. As a positive control (P+), parental NGP cells were treated with the DNA G-quadruplex stabilizer CX-5461 (50 nM) for 24 h and stained with the anti-G4 (1H6) antibody. Nuclei are counterstained with DAPI (blue). **E** Quantification of G4+ cells among 100 cells analyzed in (**D**). **F** The RS markers p-KAP1, p-Chk1, and p-RPA32 were not induced in *p53*-inactivated ATRX KO NGP cells, representing a reduction in RS. β-Tubulin was used as a loading control.
and FANCD2 have recently been reported to cooperate in replication fork recovery [29], we investigated whether FANCD2 decreases RS in the context of ATRX deficiency. We validated the knockdown efficiency of several FANCD2 shRNAs in HeLa cells and found that shRNA 3 and shRNA 4 efficiently knocked down FANCD2 at the protein level (Fig. 6A). We then measured the RS marker in two p53-inactivated ATRX KO NGP cells infected with FANCD2 shRNA. In cells lacking FANCD2 and ATRX, we observed elevated levels of γH2AX, which marks DNA damage sites, as well as stronger RS signals (Fig. 6B). Therefore, FANCD2 was required to prevent RS and ultimately genomic instability in ATRX-deficient cells, similar to BRCA2 deficiency [27, 28]. Cell proliferation assays showed that the inhibition of FANCD2 significantly decreased the survival of p53-inactivated ATRX KO NGP cells (Supplementary Fig. 11A, B). In addition, FANCD2 downregulation reduces the cell viability of ALT-positive SK-N-Fi cells (Supplementary Fig. 12A-C). Therefore, FANCD2 may be partly required for the survival of ATRX-deficient cells, suggesting a synthetic lethal relationship between them. Collectively, these results propose a key role for FANCD2 in the protection of replication forks upon the loss of ATRX in NB cells.

DISCUSSION

In the present study, ATRX deficiency activated RS and DDR through the G4 formation, leading to cell cycle arrest in TP53 wt
NB cells. Both MYCN single and MYCN amplification may activate p53 pathway in ATRX KO cells and drive RS. The synthetic lethal relationship between ATRX mutation and MYCN amplification has been reported [3]. However, TP53-truncated SK-N-AS cells were devoid of the DDR pathway upon the loss of ATRX. Moreover, the inactivation of p53 by dominant p53 mutants (R273H and R175H) in ATRX KO NGP cells rescued cell viability in response to the inhibition of ATM/CHK2/p53 pathway activation. However, the mechanisms by which the p53 status influences the effects of ATRX deficiency on the fate of NB cells currently remain unknown. Therefore, we initially demonstrated that p53 deficiency limited ATRX loss-induced RS/genome integrity in NB cells by regulating G4 helicases and the replication fork-protecting FA pathway protein, FANCD2 (Fig. 6C).

Approximately 24% of high-risk NB harboring the ALT phenotype and 50–55% of ALT NB have somatic alterations in ATRX [1, 2, 8, 9]. ALT is a HR-based mechanism, and ATRX deficiency induced the formation of G4 in the GC-rich regions of DNA, leading to replication fork stalling and the provision of a substrate for HR [11, 42]. The loss of ATRX also promoted the formation of G4 structures in untranscribed DNA strands [43]. Moreover, replication fork stalling and collapse may generate DSBs and DNA damage pathway signaling in ATRX-mutant glioma. While the loss of ATRX induces RS and DNA damage via G4 DNA, ATRX deficiency in conjunction with the chemical stabilization of G4 enhanced RS to induce DNA damage and cell death [11]. Consistent with these findings, we also observed G4 formation, RS, and DDR leading to cell cycle arrest as a consequence of ATRX deficiency in TP53 wt NB cells, supporting the findings that ATRX-negative NPCs induce excessive levels of DNA damage in the embryonic brain caused by DNA RS [15]. Moreover, the ATM/CHK2/p53 pathway was found to be activated in response to ATRX deficiency-associated DNA damage, indicating that ATRX-null cells
mostly depend on ATM-associated DDR signaling pathways for DNA repair [15, 44], which is consistent with other findings [45]. p53 inactivation or mutant TP53 with ATRX deficiency inhibited the ATM/CHK2/p53 pathway, which may be attributed to the inhibited formation of G4.

Emerging studies revealed that cancer cells with ALT were hypersensitive to the inhibition of ATR, another component of DNA damage checkpoint-activating kinases other than ATM in human cells [46]. In contrast, in several telomerase-positive and ALT-positive NB or non-NB cell lines treated with an ATR inhibitor,
ALT-positive cells were not generally more sensitive to ATR inhibition than telomerase-positive cells [34, 47]. We also did not observe the significant activation of ATR in NB cells featuring the inactivation of ATRX, which appears to support the finding that differences in ATR inhibitor sensitivity were not related to ATRX-deficient ALT [47].

While p53 inactivation rescued the survival of ATRX-deficient cells, in an attempt to identify the underlying survival mechanism, we focused on G4 helicases and their regulator, which is involved in the protection of replication forks. We hypothesized that in the absence of ATRX, other molecules may contribute to overcoming the G4 or R-loop secondary DNA structure and promoting stalled replication fork recovery, which are negatively regulated by p53. A number of p53 downregulated G4-interacting helicases that are capable of unfolding G4 structures have been reported [30–32]. They include the RECQ helicase family, WRN, BLM, RECOM, or RTEL1. WRN and BLM play major roles in unwinding G4 DNA during telomere replication [25, 26, 48–51]; however, RTEL1 has also been implicated in G4 processing and is involved in DNA replication and recombination or required for the maintenance of telomere integrity [52, 53]. RECQ helicases are strongly expressed in various cancers and their overexpression provides a survival advantage to cancer cells through the protection of stalled replication forks against breakage and possibly the restart of broken replication forks. Therefore, RECQ helicases have been proposed as a target for anticancer therapy because the inhibition of RECQ helicases induced DSBs in different origins and reduced the proliferation of cancer cell lines [48, 54]. In addition to RECQ helicases, p53 also downregulated FA DNA repair pathway proteins, such as FANC D2 and FANCJ, which are known to be involved in replication fork stabilization or the resolution of R-loops by recruiting RNA processing factors [30, 55] and G4 structures [48, 56, 57], respectively. Moreover, G4 helicases in complex with FA proteins collaborate in response to stalled replication forks [58]. In our targeted screening, FANC D2, BLM, WRN, RTEL1, and RECOM mRNA expression were increased in ATRX-deficient ALT cancer cell lines [68], suggesting its potential as an anticancer target in ALT. Therefore, as a regulator of FANC D2, FANC D2 will be an excellent target candidate for the treatment of ALT cancers.

The present results demonstrated the dependency of ATRX-deficient cells on p53 dysfunction for cellular survival. Moreover, we proposed that the dependency by these cells on the loss of p53 is mediated by G4 or R-loop resolution and replication fork stability as well as the recovery function of G4 helicases and the FA pathway protein, FANC D2. The present results may also expand the previously suggested roles of FANC D2 as a master regulator/handler of endogenous R5, thereby representing a therapeutic target for ATRX-deficient tumors. Further studies are needed to clarify the mechanisms by which ATRX deficiency interacts with the loss of p53 for NB progression and therapeutic responses.

REFERENCES
1. Valentijn LJ, Koster J, Zwijsenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47:1411–4.
2. Peifer M, Hertwig F, Roels F, Dreux D, Gartigrubler M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4.
3. Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, et al. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020;11:913.
4. Watson LA, Goldberg H, Berube NG. Emerging roles of ATR in cancer. Epigenomics. 2015;7:1365–78.
5. Fuhse J, Khare S, Wubbenhorst B, DeSloover D, D’Andrea K, Merrill S, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140.
6. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199–203.
7. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hend Lub E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteo- sarcoma. Cell Rep. 2014;7:104–12.
8. Dagg RA, Pickett HA, Neumann AA, Napier CE, Henson JD, Teber ET, et al. Extensive proliferation of human cancer cells with ever-shorter telomeres. Cell Rep. 2017;19:254–56.
9. Hartlieb SA, Sieverling L, Nadler-Holly M, Ziehm M, Toprak UH, Herrmann C, et al. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nat Commun. 2021;12:1–18.
10. George SL, Parmar V, Lorenzi F, Marshall LV, Jamin Y, Poon E, et al. Novel therapeuetic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. J Exp Clin Cancer Res. 2020;39:1–10.
11. Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, et al. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nat Commun. 2019;10:943.
12. Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, et al. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodelling. Nat Commun. 2018;9:1–15.
13. Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I, et al. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J. 2019;38:1–19.
14. Juhasz S, Elbakry A, Mathes A, Lobrich M. ATRX promotes DNA repair synthesis and sister chromatid exchange during homologous recombination. Mol Cell. 2018;71:11–24.e7.
15. Watson LA, Solomon LA, Li JR, Jiang Y, Edwards M, Shim-ya K, et al. Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span. J Clin Invest. 2013;123:2049–63.
16. Law MJ, Lower KM, Voon HP, Hughes JR, Garrick D, Viprakasit V, et al. ATR-X syndrome protein targets tandem repeats and sister chromatid exchange during homologous recombination. Mol Cell. 2018;71:11–24.e7.
17. Nguyen DT, Voon H, Xella B, Scott C, Clynes D, Babbs C, et al. The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats. EMBO Rep. 2017;18:914–9.
18. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA. 2010;107:14075–80.
19. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333:425.
Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, et al. DNA damage kinase signaling: checkpoint and replication fork protection. J Neurosci. 2008;28:12570–80.

Benedict B, van Harin T, Dekker M, Hermens S, Kucukosmanoglu A, Pieters W, et al. Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint-deficient cells. Elife. 2018;7:1–25.

Estep KN, Butler TJ, Ding J, Brosh RM. G4-interacting DNA helicases and polymerases: potential therapeutic targets. Curr Med Chem. 2019;26:2881–97.

Sauer M, Paeschke K. G-quadruplex unwinding helicases and their function in vivo. Biochim Soc Trans. 2017;45:1173–82.

Michl J, Zimmer J, Bufla FM, McDermott U, Tarsounas M. FANC2D limits replication stress and genome instability in cells lacking BRCA2. Nat Struct Mol Biol. 2016;23:755–77.

Kai S, Rundinelli B, Holmes A, O’Leary C, Kozono D, D’Andrea AD, et al. FANCD2 maintains fork stability in BRCA1/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep. 2016;15:2488–99.

Raghunandan M, Yeo JE, Walter R, Saito K, Harvey AJ, Ittershagen S, et al. Functional cross talk between the Fanconi anemia and ATRX/DAXX histone chaperone pathways promotes replication fork recovery. Hum Mol Genet. 2020;29:1083–95.

Jaber S, Toufektsian E, Lejour V, Bardot D, Toledo F. p53 downregulates the Fanconi anemia DNA repair pathway. Nat Commun. 2016;7:11091.

Simeonova I, Jaber S, Draskovic I, Bardot D, Fang M, Bouarich-Bouri M, et al. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Rep. 2015;3:2046–58.

Toufektsian E, Toledo F. The guardian of the genome revisited: p53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure. Cancers. 2018;10:135.

Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A. Functional characterization of a new p53 mutant generated by homozygous deletion in a familial and sporadic breast cancer cell line. Tumori. 2009;95:1110–6.

Georg S, Renzi P, King D, Huntie S, Campbell J, Pemberton H, et al. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. J Cell Physiol. 2019;235:2212–25.

Zhang M, Wang B, Li T, Liu R, Xiao Y, Geng X, et al. Mammalian CST averts replication stress during mild replication stress. FEBS J. 2019;286:1390–9.

Lee CY, McNerney C, Ma K, Zhao W, Wang A, Myong S. R-loop induced alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun. 2015;6:2738.

Lee CY, McNeer J, Ma K, Zhao W, Wang A, Myong S. R-loop induced G-quadruplex in non-template promotes transcription by successive R-loop formation. Nucleic Acids Res. 2014;42:8065–75.

Huang J, Zhang J, Bellani MA, Pokharel D, Gichuhi J, James RC, et al. Modelling of interstrand crosslink proximal replications is dependent on ATR, FANCM, and FANCE2D. Cell Rep. 2019;27:1794–806.e5.

ACKNOWLEDGEMENTS

We thank Mr. Daniel Mrozek (Medical English Service, Kyoto) for his English editorial assistance.
AUTHOR CONTRIBUTIONS
Conceptualization: TK and JA. Data curation: JA, YK, and PS. Formal analysis: PS, HT, MH, RPS, KM, SS, TW, KA, and TK. Resources: TK, KA, and JA. Analyzed data: JA, YK, PS, MO, RPS, and TK. Validation: JA, YK, PS, MO, and TK. Writing, reviewing & editing: JA and TK. Study supervision: TK. Project administration: TK. Funding acquisition: TK and JA.

FUNDING
This work was supported by JSPS KAKENHI Grant Number 18K15256 and a JSPS KAKENHI Grant-in-Aid for Scientific Research (B) (19H03625).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41389-021-00363-6.

Correspondence and requests for materials should be addressed to Takehiko Kamijo.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021